Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 5/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314663 | 0.94 | MCHR1 (0.54) | KMT2AMEN1SIGMAR1MCHR1ACHE | |
| SCHEMBL4314671 | 0.94 | MCHR1 (0.54) | KMT2AMEN1SIGMAR1MCHR1ACHE | |
| SCHEMBL16480389 | 0.88 | KMT2A (0.61) | KMT2AMEN1SIGMAR1POLBMCHR1 | |
| SCHEMBL3648714 | 0.88 | MCHR1 (0.48) | KMT2AMEN1SIGMAR1MCHR1ACHE | |
| SCHEMBL3648720 | 0.88 | MCHR1 (0.48) | KMT2AMEN1SIGMAR1MCHR1ACHE | |
| SCHEMBL2258425 | 0.87 | KMT2A (0.60) | KMT2AMEN1SIGMAR1POLBMCHR1 | |
| SCHEMBL13068683 | 0.85 | KMT2A (0.58) | KMT2AMEN1SIGMAR1POLBMCHR1 | |
| SCHEMBL2263432 | 0.83 | KMT2A (0.55) | KMT2AMEN1SIGMAR1POLBMCHR1 | |
| SCHEMBL28787947 | 0.82 | ACHE (0.61) | KMT2AMEN1SIGMAR1POLBACHE | |
| SCHEMBL3655207 | 0.81 | DRD4 (0.42) | SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH1, HRH2 | KMT2A 437/4885MEN1 928/4885SIGMAR1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.